ArticleJournal of applied genetics2026
Molecular and bioinformatic analysis of apoptotic tumor suppressor genes in cervical cancer.
Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the methylation status and mRNA expression of key apoptotic genes, including death-associated protein kinase (DAPK 1), tumor necrosis factor receptor superfamily member 6 (FAS), SMAC, and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and its association with clinicopathological factors in cervical cancer cases. Methylation analysis was performed on 110 cervical cancer patients using qualitative methylation-specific polymerase chain reaction (MSP). Real-time PCR was used to analyze expression levels of selected genes. All samples were also analysed for the presence of high-risk HPV types (HPV 16 and 18) with specific primer. Additionally, association with clinicopathological and risk factors were evaluated. In-silico analysis was also done for further validation. The methylation status of DAPK, TRAIL R1, SMAC, and FAS was significantly different between cancer tissues and normal tissues. DAPK (0.001), FAS (0.001), and TRAIL R1 (0.02) were hypermethylated, and SMAC was found to be hypomethylated with the highest significance of < 0.0001. HPV 16 + samples were highly significant with DAPK (0.007) and FAS (0.013), and HPV 18 + samples were significant with DAPK (0.024), FAS (0.002) and TRAIL R1 (0.009). No HPV association was found with SMAC. Methylation was found to be inversely proportional to DAPK, TRAIL R1, and FAS expression. Aberrant promoter methylation of key apoptotic genes is significantly associated with cervical cancer and may contribute to its progression. Significant correlations with HPV infection and clinicopathological factors highlight their possible potential as predictive biomarkers. However, larger studies and functional validation are needed to confirm these findings and their clinical applicability.
Indexed as
Identifiers
42393365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.